Search | Clinical Trials Finder

Conditions: Non-small Cell Lung Cancer Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1)
Interventions: SBRT with protons or photons; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer
Interventions: Total Body PET/CT Imagin; Diagnostic Test
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil, Sirolimus, Fludarabine, Total body irradiation, Hematopoietic stem cell transplant; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: treosulfan, fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, methotrexate; Drug · Radiation · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Denver, Colorado • Portland, Oregon • Seattle, Washington

Conditions: Hematologic Malignancies
Interventions: StemEx; Biological
Lead sponsor: Loyola University; Other
Eligibility: 55 Years to 73 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
Interventions: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil; Biological · Drug · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hematologic Neoplasms
Interventions: Omission of the drug mycophenolate mofetil; Other
Lead sponsor: Ronald Paquette; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: SPECT/CT; Diagnostic Test
Lead sponsor: BAMF Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Traumatic Brain Injury
Interventions: Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI), Brain Health Group (BHG); Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Congenital Amegakaryocytic Thrombocytopenia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions: anti-thymocyte globulin, therapeutic allogeneic lymphocytes, fludarabine phosphate, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: San Francisco, California • Chapel Hill, North Carolina

Conditions: Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Indium In-111 Ibritumomab Tiuxetan, Mycophenolate Mofetil, Pharmacological Study, Rituximab, Total-Body Irradiation, Yttrium Y-90 Ibritumomab Tiuxetan, Fludarabine; Procedure · Drug · Radiation + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Leukemia
Interventions: Busulfan, Fludarabine, Thymoglobulin, Total Body Irradiation; Drug · Radiation
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hematologic Neoplasms
Interventions: Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI); Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiotherapy, Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Radiation · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Stereotactic body radiotherapy (SBRT) Boost; Radiation
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2029
U.S. locations: 3
States / cities: Fountain Valley, California • Laguna Hills, California • Long Beach, California

Conditions: Primary Tumor, Renal Cell Carcinoma
Interventions: Stereotactic Body Radiotherapy (SBRT); Radiation
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: New York, New York

Conditions: Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions: Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography; Drug · Biological · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis; Radiation · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 16 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Resectable Pancreatic Cancer
Interventions: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1, -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours; Other · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Aplastic
Interventions: Cyclophosphamide,Campath IH and TBI; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Weight Loss
Interventions: Advantra Z, Advantra Z + Naringin + Hesperiden, Sugar pill; Dietary Supplement · Other
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatocellular Carcinoma
Interventions: SBRT, TACE; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Interventions: stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis, androgen deprivation therapy; Radiation · Other · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions: Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant; Drug · Radiation · Device + 1 more
Lead sponsor: Alice Bertaina; Other
Eligibility: 1 Year to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Umbilical Cord Transplantation for the Elderly Population

Allo HSCT Using RIC and PTCy for Hematological Diseases

Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

Expanding Delivery of an Evidence-based Weight-loss Intervention to Enhance Access and Reach Underserved Groups After TBI

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

SBRT Boost for Unfavorable Prostate Cancer'

To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Borderline Pancreas Study: FOLFIRINOX +SBRT

Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia

A Comparative Effectiveness Study Evaluating the Effects of Thermogenic Supplements on Body Composition

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor